Intravenous Interferon During Liver Transplant

Wake Forest University (WFU)

Status: Completed

Conditions: Cirrhosis; Hepatitis C

Treatments: Drug: IV interferon

Study type: Interventional

Funder types: Other

Identifiers

NCT01192698

04-05-09A

Details and patient eligibility

About

The main goal of this study is to prevent liver allograft infection with Hepatitis C virus in hepatitis C positive patients undergoing liver transplantation. The hypothesis is that patients who receive ribavirin immediately before transplant and intravenous interferon alfa 2b during the anhepatic phase(while the liver is removed)will have sustained virologic response post liver transplant.

Full description

The study is evaluating intravenous interferon given during the anhepatic phase of lvier transplant. Ribavirin was given as well. Serial measurements for HCV RNA were determined 12, 24 72, 96 hrs and 4 weeks after liver transplant.

Enrollment: 15 patients

Sex: All

Ages: 18 to 70 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• liver transplant for hepatitis c

Exclusion criteria

• allergy to interferon

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

15 participants in 2 patient groups

IV interferon

Experimental group

Description:

IV interferon oral ribavirin

Treatment:

Drug: IV interferon

Standard of care

No Intervention group

Description:

standard of care